
Rybrevant Faspro won accelerated approval for recurrent or metastatic HNSCC after a trial showed a 42% response rate in previously treated patients.
Healthcare spending is expected to dip in 2013, but projections indicate that the spending could jump significantly in 2014 because of PPACA.






